Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2025 06:05 ET | Source: Precede Biosciences, Inc.

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Precede Biosciences Presents New Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in SCLC
September 08, 2025 11:00 ET | Source: BioNTech SE

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs

Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und...
September 08, 2025 11:00 ET | Source: BioNTech SE

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”),...
March 25, 2025 08:30 ET | Source: Genelux Corporation

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a...
January 17, 2025 08:23 ET | Source: Transparency Market Research

Lung Cancer Diagnostics Market Set to Revolutionize Early Detection, projected to Reach US$ 34.8 Billion by 2034, Driven by Technological Innovations and Growing Global Demand | TMR

Wilmington, Delaware, Transparency Market Research Inc. –, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global lung cancer diagnostics market is projected to experience substantial growth in the coming...
March 21, 2024 09:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
November 01, 2023 06:46 ET | Source: The Insight Partners

Lung Cancer Therapy Market Share Worth $80.49 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly...
October 13, 2023 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL...
May 05, 2023 12:30 ET | Source: Transparency Market Research

Small Cell Lung Cancer Therapeutics Market Value to Exceed of USD 12.9 Bn by 2031, rising at a 11.9% CAGR: TMR Report

Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global small cell lung cancer therapeutics market was valued at USD 4.6 Bn in 2022 and is projected to expand at a CAGR of...
April 26, 2023 06:30 ET | Source: Transparency Market Research

USD 12.6 Bn Cancer Biomarkers Market to Grow at a CAGR of 9.9% During 2022 to 2031 - Global Analysis by Transparency Market Research

Wilmington, Delaware, United States, April 26, 2023 (GLOBE NEWSWIRE) -- According to Transparency Market Research, tThe global cancer biomarkers market size stood at USD 12.6 Bn in 2021. The market...